- Home
- TALK vs BCAX Comparison
TALK vs BCAX Comparison
Compare TALK & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALK
- BCAX
- Stock Information
- Founded
- TALK 2012
- BCAX 2018
- Country
- TALK United States
- BCAX United States
- Employees
- TALK N/A
- BCAX N/A
- Industry
- TALK Medical/Nursing Services
- BCAX
- Sector
- TALK Health Care
- BCAX
- Exchange
- TALK Nasdaq
- BCAX NYSE
- Market Cap
- TALK 476.8M
- BCAX 487.6M
- IPO Year
- TALK N/A
- BCAX 2024
- Fundamental
- Price
- TALK $2.64
- BCAX $9.71
- Analyst Decision
- TALK Buy
- BCAX Strong Buy
- Analyst Count
- TALK 6
- BCAX 7
- Target Price
- TALK $4.50
- BCAX $29.17
- AVG Volume (30 Days)
- TALK 1.6M
- BCAX 684.2K
- Earning Date
- TALK 08-05-2025
- BCAX 08-16-2025
- Dividend Yield
- TALK N/A
- BCAX N/A
- EPS Growth
- TALK N/A
- BCAX N/A
- EPS
- TALK 0.02
- BCAX N/A
- Revenue
- TALK $194,359,000.00
- BCAX N/A
- Revenue This Year
- TALK $22.39
- BCAX N/A
- Revenue Next Year
- TALK $20.33
- BCAX N/A
- P/E Ratio
- TALK $152.05
- BCAX N/A
- Revenue Growth
- TALK 19.88
- BCAX N/A
- 52 Week Low
- TALK $1.60
- BCAX $7.80
- 52 Week High
- TALK $4.36
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- TALK 41.51
- BCAX N/A
- Support Level
- TALK $2.63
- BCAX N/A
- Resistance Level
- TALK $2.83
- BCAX N/A
- Average True Range (ATR)
- TALK 0.11
- BCAX 0.00
- MACD
- TALK 0.00
- BCAX 0.00
- Stochastic Oscillator
- TALK 10.71
- BCAX 0.00
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.